Catalyst Pharmaceuticals, Inc. (CPRX) 10-Year Financial Performance & Capital Metrics

CPRX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Show more

Revenue $492M +23.5%
EBITDA $233M +94.6%
Net Income $164M +129.5%
EPS (Diluted) 1.31 +107.9%
Gross Margin 86% -1.1%
EBITDA Margin 47.36% +57.6%
Operating Margin 39.68% +82.0%
Net Margin 33.33% +85.9%
ROE 29.38% +41.6%
ROIC 62.66% +25.0%
Debt/Equity 0.00 -52.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 27.6%
✓Strong 5Y profit CAGR of 38.7%
✓FCF machine: 48.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 36.9%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y36.89%

3Y51.71%

TTM25.56%

Profit (Net Income) CAGR

10Y-

5Y38.75%

3Y60.71%

TTM52.36%

EPS CAGR

10Y-

5Y34.29%

3Y52.41%

TTM45.76%

ROCE

10Y Avg3.54%

5Y Avg31.44%

3Y Avg32.53%

Latest34.7%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	102.31M	119.07M	140.83M	214.2M	398.2M	491.73M
Revenue Growth %	-	-	-	-	203.61%	0.16%	0.18%	0.52%	0.86%	0.23%
Cost of Goods Sold+	34.47K	43.41K	45.69K	19.92M	14.76M	17.04M	21.88M	34.39M	51.97M	68.84M
COGS % of Revenue	-	-	-	39.84%	0.14%	0.14%	0.16%	0.16%	0.13%	0.14%
Gross Profit+	-34.47K	-43.41K	-45.69K	-19.42M	87.55M	102.03M	118.95M	179.81M	346.24M	422.89M
Gross Margin %	-	-	-	-38.84%	0.86%	0.86%	0.84%	0.84%	0.87%	0.86%
Gross Profit Growth %	-	-0.26%	-0.05%	-424.03%	5.51%	0.17%	0.17%	0.51%	0.93%	0.22%
Operating Expenses+	20.4M	19.28M	18.68M	35.8M	55.72M	60.73M	66.56M	77.97M	259.43M	227.76M
OpEx % of Revenue	-	-	-	71.59%	0.54%	0.51%	0.47%	0.36%	0.65%	0.46%
Selling, General & Admin	8.6M	7.91M	7.3M	15.88M	36.88M	44.23M	49.63M	57.09M	133.71M	177.74M
SG&A % of Revenue	-	-	-	31.75%	0.36%	0.37%	0.35%	0.27%	0.34%	0.36%
Research & Development	11.8M	11.37M	11.38M	19.92M	18.84M	16.5M	16.94M	19.79M	93.15M	12.65M
R&D % of Revenue	-	-	-	39.84%	0.18%	0.14%	0.12%	0.09%	0.23%	0.03%
Other Operating Expenses	100.39K	0	0	1.29M	0	0	0	1.1M	32.56M	37.38M
Operating Income+	-20.4M	-19.28M	-18.68M	-35.3M	31.82M	41.3M	52.38M	101.84M	86.81M	195.12M
Operating Margin %	-	-	-	-70.59%	0.31%	0.35%	0.37%	0.48%	0.22%	0.4%
Operating Income Growth %	-0.4%	0.05%	0.03%	-0.89%	1.9%	0.3%	0.27%	0.94%	-0.15%	1.25%
EBITDA+	-20.36M	-19.24M	-18.63M	-35.26M	31.88M	41.4M	52.58M	103.08M	119.69M	232.9M
EBITDA Margin %	-	-	-	-70.51%	0.31%	0.35%	0.37%	0.48%	0.3%	0.47%
EBITDA Growth %	-0.4%	0.06%	0.03%	-0.89%	1.9%	0.3%	0.27%	0.96%	0.16%	0.95%
D&A (Non-Cash Add-back)	34.47K	43.41K	45.69K	37.98K	55K	92K	192K	1.24M	32.88M	37.77M
EBIT	-20.23M	-18.07M	-18.41M	-35.3M	31.82M	41.3M	52.38M	101.84M	86.81M	195.12M
Net Interest Income+	0	0	0	1.29M	1.59M	0	0	0	0	16.06M
Interest Income	100.39K	321.61K	454.16K	1.29M	1.59M	0	0	0	0	16.06M
Interest Expense	100.39K	321.61K	454.16K	0	0	0	0	0	0	0
Other Income/Expense	165.39K	1.21M	267.26K	1.29M	1.59M	587K	282K	2.88M	7.7M	21.14M
Pretax Income+	-20.23M	-18.07M	-18.41M	-34M	33.41M	41.89M	52.67M	104.72M	94.51M	216.26M
Pretax Margin %	-	-	-	-68.01%	0.33%	0.35%	0.37%	0.49%	0.24%	0.44%
Income Tax+	-99.47K	0	141.22K	0	1.53M	-33.09M	13.19M	21.64M	23.1M	52.37M
Effective Tax Rate %	1%	1%	1%	1%	0.95%	1.79%	0.75%	0.79%	0.76%	0.76%
Net Income+	-20.23M	-18.07M	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M
Net Margin %	-	-	-	-68.01%	0.31%	0.63%	0.28%	0.39%	0.18%	0.33%
Net Income Growth %	-0.3%	0.11%	-0.02%	-0.85%	1.94%	1.35%	-0.47%	1.1%	-0.14%	1.3%
Net Income (Continuing)	-20.23M	-18.07M	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.22	-0.21	-0.33	0.30	0.71	0.37	0.75	0.63	1.31
EPS Growth %	-0.04%	0.12%	0.05%	-0.57%	1.91%	1.37%	-0.48%	1.03%	-0.16%	1.08%
EPS (Basic)	-0.25	-0.22	-0.21	-0.33	0.31	0.72	0.38	0.80	0.67	1.38
Diluted Shares Outstanding	80.86M	82.88M	85.8M	102.63M	106.02M	106.24M	107.8M	111.38M	113.75M	124.94M
Basic Shares Outstanding	80.86M	82.88M	85.8M	102.63M	102.94M	103.51M	103.38M	103.37M	106.28M	118.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	59.9M	41.45M	85.19M	55.19M	111.36M	159.24M	210.11M	320.81M	219.33M	623.61M
Cash & Short-Term Investments	58.4M	40.41M	84.01M	53.48M	94.52M	140.28M	191.27M	298.39M	137.64M	517.55M
Cash Only	28.24M	13.89M	57.5M	16.56M	89.51M	130.24M	171.44M	298.39M	137.64M	517.55M
Short-Term Investments	30.16M	26.51M	26.52M	36.92M	5.01M	10.04M	19.82M	0	0	0
Accounts Receivable	0	0	0	0	10.54M	5.99M	6.72M	10.79M	53.51M	65.49M
Days Sales Outstanding	-	-	-	-	37.59	18.35	17.43	18.39	49.05	48.61
Inventory	0	0	0	56.01K	1.96M	4.65M	7.87M	6.8M	15.64M	19.54M
Days Inventory Outstanding	-	-	-	1.03	48.39	99.63	131.26	72.22	109.88	103.6
Other Current Assets	34.72K	36.44K	58.28K	272.17K	516.66K	883K	327K	0	489K	1.03M
Total Non-Current Assets+	200.44K	253.09K	200.27K	5.26M	1.01M	33.11M	27.68M	54.82M	250.78M	227.8M
Property, Plant & Equipment	191.55K	244.2K	191.38K	245.43K	1M	130K	3.98M	3.62M	3.7M	3.58M
Fixed Asset Turnover	-	-	-	2.04x	101.93x	915.95x	35.42x	59.22x	107.54x	137.20x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	32.47M	194.05M	156.67M
Long-Term Investments	0	0	0	5.01M	0	0	0	0	16.49M	21.56M
Other Non-Current Assets	8.89K	8.89K	8.89K	8.89K	8.89K	9K	9K	0	0	0
Total Assets+	60.1M	41.71M	85.39M	60.45M	112.38M	192.35M	237.79M	375.63M	470.11M	851.41M
Asset Turnover	-	-	-	0.01x	0.91x	0.62x	0.59x	0.57x	0.85x	0.58x
Asset Growth %	0.37%	-0.31%	1.05%	-0.29%	0.86%	0.71%	0.24%	0.58%	0.25%	0.81%
Total Current Liabilities+	3.44M	2.09M	4.27M	9.51M	24.1M	22.76M	27.06M	57.59M	76.06M	120.68M
Accounts Payable	1.79M	933.18K	1.95M	2.34M	4.12M	4.26M	2.77M	3.98M	14.79M	16.59M
Days Payables Outstanding	19K	7.85K	15.54K	42.83	101.83	91.17	46.17	42.19	103.92	87.97
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	18.09K	18.09K	24.01K	0	0	0	0	0	0	0
Other Current Liabilities	751.63K	897.12K	1.5M	2.04M	3.24M	4.1M	4.28M	5.37M	51.29M	11.16M
Current Ratio	17.41x	19.79x	19.97x	5.80x	4.62x	7.00x	7.76x	5.57x	2.88x	5.17x
Quick Ratio	17.41x	19.79x	19.97x	5.80x	4.54x	6.79x	7.47x	5.45x	2.68x	5.01x
Cash Conversion Cycle	-	-	-	-	-15.84	26.81	102.52	48.42	55.01	64.24
Total Non-Current Liabilities+	1.18M	303.39K	157.46K	154.8K	647.53K	0	3.89M	17.62M	6.17M	3.1M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	647.53K	0	3.89M	3.56M	3.19M	2.79M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.18M	303.39K	157.46K	154.8K	0	0	0	14.06M	2.98M	315K
Total Liabilities	4.63M	2.4M	4.42M	9.67M	24.75M	22.76M	30.96M	75.21M	82.23M	123.78M
Total Debt+	0	0	0	0	948.05K	29K	4.2M	3.89M	3.56M	3.19M
Net Debt	-28.24M	-13.89M	-57.5M	-16.56M	-88.56M	-130.21M	-167.24M	-294.5M	-134.08M	-514.37M
Debt / Equity	-	-	-	-	0.01x	0.00x	0.02x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	0.03x	0.00x	0.08x	0.04x	0.03x	0.01x
Net Debt / EBITDA	-	-	-	-	-2.78x	-3.15x	-3.18x	-2.86x	-1.12x	-2.21x
Interest Coverage	-203.19x	-59.95x	-41.13x	-	-	-	-	-	-	-
Total Equity+	55.48M	39.31M	80.96M	50.78M	87.63M	169.6M	206.83M	300.42M	387.88M	727.63M
Equity Growth %	0.57%	-0.29%	1.06%	-0.37%	0.73%	0.94%	0.22%	0.45%	0.29%	0.88%
Book Value per Share	0.69	0.47	0.94	0.49	0.83	1.60	1.92	2.70	3.41	5.82
Total Shareholders' Equity	55.48M	39.31M	80.96M	50.78M	87.63M	169.6M	206.83M	300.42M	387.88M	727.63M
Common Stock	82.85K	82.97K	102.55K	102.74K	103.4K	104K	103K	105K	107K	121K
Retained Earnings	-90.08M	-108.15M	-126.56M	-160.56M	-128.69M	-53.7M	-26.31M	49.86M	121.27M	285.16M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-70.07K	-113.48K	-159.17K	-20.25K	9.51K	31K	-148K	24K	14K	64K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.02M	-17.96M	-13.74M	-25.7M	34.61M	45.03M	60.37M	116.05M	143.6M	239.81M
Operating CF Margin %	-	-	-	-51.41%	0.34%	0.38%	0.43%	0.54%	0.36%	0.49%
Operating CF Growth %	-0.39%	0%	0.23%	-0.87%	2.35%	0.3%	0.34%	0.92%	0.24%	0.67%
Net Income	-20.23M	-18.07M	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M
Depreciation & Amortization	34.47K	43.41K	45.69K	37.98K	297.73K	885.32K	192K	1.24M	32.88M	37.77M
Stock-Based Compensation	1.59M	1.84M	2.41M	3.55M	0	0	6.07M	7.91M	14.25M	22.25M
Deferred Taxes	-1.65M	0	0	0	0	-32.97M	9.32M	4.94M	-17.82M	-9.39M
Other Non-Cash Items	1.59M	-886.14K	186.9K	3.68M	3.53M	6.25M	287K	5.16M	80.2M	-5.63M
Working Capital Changes	662.82K	-884.4K	2.03M	4.71M	-1.1M	-4.11M	5.02M	13.73M	-37.32M	30.91M
Change in Receivables	0	0	0	0	-10.54M	4.55M	-632K	-3.82M	-43.08M	-11.96M
Change in Inventory	0	0	0	-56.01K	-1.9M	-2.69M	-3.22M	1.06M	-4.74M	-3.9M
Change in Payables	-20.08K	-860.95K	1.01M	391.79K	1.78M	138.57K	-1.49M	1.21M	10.82M	1.8M
Cash from Investing+	-6.5K	3.55M	-3.96K	-15.53M	37.22M	-5.01M	-11.02M	9.21M	-293.5M	-556K
Capital Expenditures	-23.46K	-96.06K	0	-92.02K	-19.37K	-11.4K	-1.02M	-29K	-231K	-556K
CapEx % of Revenue	-	-	-	0.18%	0%	0%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-23.46K	-23.46K	-3.96K	-14.99M	0	0	0	-10M	-279.81M	0
Cash from Financing+	37.16M	68.99K	57.35M	293.12K	1.12M	701.93K	-8.14M	1.69M	-10.86M	140.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.29M	68.99K	3.58M	293.12K	0	-56.2K	3.95M	8.6M	-10.86M	-39K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.04M	-18.06M	-13.74M	-25.8M	34.59M	45.02M	59.35M	116.02M	61.86M	239.25M
FCF Margin %	-	-	-	-51.59%	0.34%	0.38%	0.42%	0.54%	0.16%	0.49%
FCF Growth %	-0.39%	-0%	0.24%	-0.88%	2.34%	0.3%	0.32%	0.95%	-0.47%	2.87%
FCF per Share	-0.22	-0.22	-0.16	-0.25	0.33	0.42	0.55	1.04	0.54	1.91
FCF Conversion (FCF/Net Income)	0.89x	0.99x	0.75x	0.76x	1.09x	0.60x	1.53x	1.40x	2.01x	1.46x
Interest Paid	0	0	0	0	0	0	0	0	705K	1.4M
Taxes Paid	0	0	0	0	0	0	3M	7.67M	50.46M	68.45M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-44.61%	-38.13%	-30.62%	-51.62%	46.06%	58.3%	20.98%	32.76%	20.75%	29.38%
Return on Invested Capital (ROIC)	-57.31%	-54.92%	-57.32%	-91.77%	143.39%	161.1%	99.49%	335.67%	50.14%	62.66%
Gross Margin	-	-	-	-3883.84%	85.57%	85.69%	84.46%	83.94%	86.95%	86%
Net Margin	-	-	-	-6800.7%	31.16%	62.97%	28.03%	38.79%	17.93%	33.33%
Debt / Equity	-	-	-	-	0.01x	0.00x	0.02x	0.01x	0.01x	0.00x
Interest Coverage	-203.19x	-59.95x	-41.13x	-	-	-	-	-	-	-
FCF Conversion	0.89x	0.99x	0.75x	0.76x	1.09x	0.60x	1.53x	1.40x	2.01x	1.46x
Revenue Growth	-	-	-	-	20361.2%	16.39%	18.27%	52.1%	85.9%	23.49%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Product Revenue Net	-	-	138M	213.94M	396.5M	489.33M
Product Revenue Net Growth	-	-	-	55.03%	85.34%	23.41%
License And Other Revenue	-	-	2.84M	265K	1.7M	2.41M
License And Other Revenue Growth	-	-	-	-90.66%	542.26%	41.42%
Product	102.31M	-	-	-	-	-
Product Growth	-	-	-	-	-	-
Collaborative Arrangement Products Agreement	-	-	-	-	-	-
Collaborative Arrangement Products Agreement Growth	-	-	-	-	-	-

Revenue by Geography

	2019	2020	2021	2022	2023	2024
CANADA	-	33K	-	-	-	-
CANADA Growth	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Catalyst Pharmaceuticals, Inc. (CPRX) has a price-to-earnings (P/E) ratio of 17.7x. This is roughly in line with market averages.

Growth & Financials

Catalyst Pharmaceuticals, Inc. (CPRX) reported $578.2M in revenue for fiscal year 2024.

Catalyst Pharmaceuticals, Inc. (CPRX) grew revenue by 23.5% over the past year. This is strong growth.

Yes, Catalyst Pharmaceuticals, Inc. (CPRX) is profitable, generating $217.6M in net income for fiscal year 2024 (33.3% net margin).

Dividend & Returns

Catalyst Pharmaceuticals, Inc. (CPRX) has a return on equity (ROE) of 29.4%. This is excellent, indicating efficient use of shareholder capital.

Catalyst Pharmaceuticals, Inc. (CPRX) generated $234.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Catalyst Pharmaceuticals, Inc. (CPRX) 10-Year Financial Performance & Capital Metrics

CPRX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $492M +23.5%
EBITDA $233M +94.6%
Net Income $164M +129.5%
EPS (Diluted) 1.31 +107.9%
Gross Margin 86% -1.1%
EBITDA Margin 47.36% +57.6%
Operating Margin 39.68% +82.0%
Net Margin 33.33% +85.9%
ROE 29.38% +41.6%
ROIC 62.66% +25.0%
Debt/Equity 0.00 -52.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 27.6%
✓Strong 5Y profit CAGR of 38.7%
✓FCF machine: 48.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 36.9%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y36.89%

3Y51.71%

TTM25.56%

Profit (Net Income) CAGR

10Y-

5Y38.75%

3Y60.71%

TTM52.36%

EPS CAGR

10Y-

5Y34.29%

3Y52.41%

TTM45.76%

ROCE

10Y Avg3.54%

5Y Avg31.44%

3Y Avg32.53%

Latest34.7%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	102.31M	119.07M	140.83M	214.2M	398.2M	491.73M
Revenue Growth %	-	-	-	-	203.61%	0.16%	0.18%	0.52%	0.86%	0.23%
Cost of Goods Sold+	34.47K	43.41K	45.69K	19.92M	14.76M	17.04M	21.88M	34.39M	51.97M	68.84M
COGS % of Revenue	-	-	-	39.84%	0.14%	0.14%	0.16%	0.16%	0.13%	0.14%
Gross Profit+	-34.47K	-43.41K	-45.69K	-19.42M	87.55M	102.03M	118.95M	179.81M	346.24M	422.89M
Gross Margin %	-	-	-	-38.84%	0.86%	0.86%	0.84%	0.84%	0.87%	0.86%
Gross Profit Growth %	-	-0.26%	-0.05%	-424.03%	5.51%	0.17%	0.17%	0.51%	0.93%	0.22%
Operating Expenses+	20.4M	19.28M	18.68M	35.8M	55.72M	60.73M	66.56M	77.97M	259.43M	227.76M
OpEx % of Revenue	-	-	-	71.59%	0.54%	0.51%	0.47%	0.36%	0.65%	0.46%
Selling, General & Admin	8.6M	7.91M	7.3M	15.88M	36.88M	44.23M	49.63M	57.09M	133.71M	177.74M
SG&A % of Revenue	-	-	-	31.75%	0.36%	0.37%	0.35%	0.27%	0.34%	0.36%
Research & Development	11.8M	11.37M	11.38M	19.92M	18.84M	16.5M	16.94M	19.79M	93.15M	12.65M
R&D % of Revenue	-	-	-	39.84%	0.18%	0.14%	0.12%	0.09%	0.23%	0.03%
Other Operating Expenses	100.39K	0	0	1.29M	0	0	0	1.1M	32.56M	37.38M
Operating Income+	-20.4M	-19.28M	-18.68M	-35.3M	31.82M	41.3M	52.38M	101.84M	86.81M	195.12M
Operating Margin %	-	-	-	-70.59%	0.31%	0.35%	0.37%	0.48%	0.22%	0.4%
Operating Income Growth %	-0.4%	0.05%	0.03%	-0.89%	1.9%	0.3%	0.27%	0.94%	-0.15%	1.25%
EBITDA+	-20.36M	-19.24M	-18.63M	-35.26M	31.88M	41.4M	52.58M	103.08M	119.69M	232.9M
EBITDA Margin %	-	-	-	-70.51%	0.31%	0.35%	0.37%	0.48%	0.3%	0.47%
EBITDA Growth %	-0.4%	0.06%	0.03%	-0.89%	1.9%	0.3%	0.27%	0.96%	0.16%	0.95%
D&A (Non-Cash Add-back)	34.47K	43.41K	45.69K	37.98K	55K	92K	192K	1.24M	32.88M	37.77M
EBIT	-20.23M	-18.07M	-18.41M	-35.3M	31.82M	41.3M	52.38M	101.84M	86.81M	195.12M
Net Interest Income+	0	0	0	1.29M	1.59M	0	0	0	0	16.06M
Interest Income	100.39K	321.61K	454.16K	1.29M	1.59M	0	0	0	0	16.06M
Interest Expense	100.39K	321.61K	454.16K	0	0	0	0	0	0	0
Other Income/Expense	165.39K	1.21M	267.26K	1.29M	1.59M	587K	282K	2.88M	7.7M	21.14M
Pretax Income+	-20.23M	-18.07M	-18.41M	-34M	33.41M	41.89M	52.67M	104.72M	94.51M	216.26M
Pretax Margin %	-	-	-	-68.01%	0.33%	0.35%	0.37%	0.49%	0.24%	0.44%
Income Tax+	-99.47K	0	141.22K	0	1.53M	-33.09M	13.19M	21.64M	23.1M	52.37M
Effective Tax Rate %	1%	1%	1%	1%	0.95%	1.79%	0.75%	0.79%	0.76%	0.76%
Net Income+	-20.23M	-18.07M	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M
Net Margin %	-	-	-	-68.01%	0.31%	0.63%	0.28%	0.39%	0.18%	0.33%
Net Income Growth %	-0.3%	0.11%	-0.02%	-0.85%	1.94%	1.35%	-0.47%	1.1%	-0.14%	1.3%
Net Income (Continuing)	-20.23M	-18.07M	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.25	-0.22	-0.21	-0.33	0.30	0.71	0.37	0.75	0.63	1.31
EPS Growth %	-0.04%	0.12%	0.05%	-0.57%	1.91%	1.37%	-0.48%	1.03%	-0.16%	1.08%
EPS (Basic)	-0.25	-0.22	-0.21	-0.33	0.31	0.72	0.38	0.80	0.67	1.38
Diluted Shares Outstanding	80.86M	82.88M	85.8M	102.63M	106.02M	106.24M	107.8M	111.38M	113.75M	124.94M
Basic Shares Outstanding	80.86M	82.88M	85.8M	102.63M	102.94M	103.51M	103.38M	103.37M	106.28M	118.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	59.9M	41.45M	85.19M	55.19M	111.36M	159.24M	210.11M	320.81M	219.33M	623.61M
Cash & Short-Term Investments	58.4M	40.41M	84.01M	53.48M	94.52M	140.28M	191.27M	298.39M	137.64M	517.55M
Cash Only	28.24M	13.89M	57.5M	16.56M	89.51M	130.24M	171.44M	298.39M	137.64M	517.55M
Short-Term Investments	30.16M	26.51M	26.52M	36.92M	5.01M	10.04M	19.82M	0	0	0
Accounts Receivable	0	0	0	0	10.54M	5.99M	6.72M	10.79M	53.51M	65.49M
Days Sales Outstanding	-	-	-	-	37.59	18.35	17.43	18.39	49.05	48.61
Inventory	0	0	0	56.01K	1.96M	4.65M	7.87M	6.8M	15.64M	19.54M
Days Inventory Outstanding	-	-	-	1.03	48.39	99.63	131.26	72.22	109.88	103.6
Other Current Assets	34.72K	36.44K	58.28K	272.17K	516.66K	883K	327K	0	489K	1.03M
Total Non-Current Assets+	200.44K	253.09K	200.27K	5.26M	1.01M	33.11M	27.68M	54.82M	250.78M	227.8M
Property, Plant & Equipment	191.55K	244.2K	191.38K	245.43K	1M	130K	3.98M	3.62M	3.7M	3.58M
Fixed Asset Turnover	-	-	-	2.04x	101.93x	915.95x	35.42x	59.22x	107.54x	137.20x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	32.47M	194.05M	156.67M
Long-Term Investments	0	0	0	5.01M	0	0	0	0	16.49M	21.56M
Other Non-Current Assets	8.89K	8.89K	8.89K	8.89K	8.89K	9K	9K	0	0	0
Total Assets+	60.1M	41.71M	85.39M	60.45M	112.38M	192.35M	237.79M	375.63M	470.11M	851.41M
Asset Turnover	-	-	-	0.01x	0.91x	0.62x	0.59x	0.57x	0.85x	0.58x
Asset Growth %	0.37%	-0.31%	1.05%	-0.29%	0.86%	0.71%	0.24%	0.58%	0.25%	0.81%
Total Current Liabilities+	3.44M	2.09M	4.27M	9.51M	24.1M	22.76M	27.06M	57.59M	76.06M	120.68M
Accounts Payable	1.79M	933.18K	1.95M	2.34M	4.12M	4.26M	2.77M	3.98M	14.79M	16.59M
Days Payables Outstanding	19K	7.85K	15.54K	42.83	101.83	91.17	46.17	42.19	103.92	87.97
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	18.09K	18.09K	24.01K	0	0	0	0	0	0	0
Other Current Liabilities	751.63K	897.12K	1.5M	2.04M	3.24M	4.1M	4.28M	5.37M	51.29M	11.16M
Current Ratio	17.41x	19.79x	19.97x	5.80x	4.62x	7.00x	7.76x	5.57x	2.88x	5.17x
Quick Ratio	17.41x	19.79x	19.97x	5.80x	4.54x	6.79x	7.47x	5.45x	2.68x	5.01x
Cash Conversion Cycle	-	-	-	-	-15.84	26.81	102.52	48.42	55.01	64.24
Total Non-Current Liabilities+	1.18M	303.39K	157.46K	154.8K	647.53K	0	3.89M	17.62M	6.17M	3.1M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	647.53K	0	3.89M	3.56M	3.19M	2.79M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.18M	303.39K	157.46K	154.8K	0	0	0	14.06M	2.98M	315K
Total Liabilities	4.63M	2.4M	4.42M	9.67M	24.75M	22.76M	30.96M	75.21M	82.23M	123.78M
Total Debt+	0	0	0	0	948.05K	29K	4.2M	3.89M	3.56M	3.19M
Net Debt	-28.24M	-13.89M	-57.5M	-16.56M	-88.56M	-130.21M	-167.24M	-294.5M	-134.08M	-514.37M
Debt / Equity	-	-	-	-	0.01x	0.00x	0.02x	0.01x	0.01x	0.00x
Debt / EBITDA	-	-	-	-	0.03x	0.00x	0.08x	0.04x	0.03x	0.01x
Net Debt / EBITDA	-	-	-	-	-2.78x	-3.15x	-3.18x	-2.86x	-1.12x	-2.21x
Interest Coverage	-203.19x	-59.95x	-41.13x	-	-	-	-	-	-	-
Total Equity+	55.48M	39.31M	80.96M	50.78M	87.63M	169.6M	206.83M	300.42M	387.88M	727.63M
Equity Growth %	0.57%	-0.29%	1.06%	-0.37%	0.73%	0.94%	0.22%	0.45%	0.29%	0.88%
Book Value per Share	0.69	0.47	0.94	0.49	0.83	1.60	1.92	2.70	3.41	5.82
Total Shareholders' Equity	55.48M	39.31M	80.96M	50.78M	87.63M	169.6M	206.83M	300.42M	387.88M	727.63M
Common Stock	82.85K	82.97K	102.55K	102.74K	103.4K	104K	103K	105K	107K	121K
Retained Earnings	-90.08M	-108.15M	-126.56M	-160.56M	-128.69M	-53.7M	-26.31M	49.86M	121.27M	285.16M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-70.07K	-113.48K	-159.17K	-20.25K	9.51K	31K	-148K	24K	14K	64K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.02M	-17.96M	-13.74M	-25.7M	34.61M	45.03M	60.37M	116.05M	143.6M	239.81M
Operating CF Margin %	-	-	-	-51.41%	0.34%	0.38%	0.43%	0.54%	0.36%	0.49%
Operating CF Growth %	-0.39%	0%	0.23%	-0.87%	2.35%	0.3%	0.34%	0.92%	0.24%	0.67%
Net Income	-20.23M	-18.07M	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M
Depreciation & Amortization	34.47K	43.41K	45.69K	37.98K	297.73K	885.32K	192K	1.24M	32.88M	37.77M
Stock-Based Compensation	1.59M	1.84M	2.41M	3.55M	0	0	6.07M	7.91M	14.25M	22.25M
Deferred Taxes	-1.65M	0	0	0	0	-32.97M	9.32M	4.94M	-17.82M	-9.39M
Other Non-Cash Items	1.59M	-886.14K	186.9K	3.68M	3.53M	6.25M	287K	5.16M	80.2M	-5.63M
Working Capital Changes	662.82K	-884.4K	2.03M	4.71M	-1.1M	-4.11M	5.02M	13.73M	-37.32M	30.91M
Change in Receivables	0	0	0	0	-10.54M	4.55M	-632K	-3.82M	-43.08M	-11.96M
Change in Inventory	0	0	0	-56.01K	-1.9M	-2.69M	-3.22M	1.06M	-4.74M	-3.9M
Change in Payables	-20.08K	-860.95K	1.01M	391.79K	1.78M	138.57K	-1.49M	1.21M	10.82M	1.8M
Cash from Investing+	-6.5K	3.55M	-3.96K	-15.53M	37.22M	-5.01M	-11.02M	9.21M	-293.5M	-556K
Capital Expenditures	-23.46K	-96.06K	0	-92.02K	-19.37K	-11.4K	-1.02M	-29K	-231K	-556K
CapEx % of Revenue	-	-	-	0.18%	0%	0%	0.01%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-23.46K	-23.46K	-3.96K	-14.99M	0	0	0	-10M	-279.81M	0
Cash from Financing+	37.16M	68.99K	57.35M	293.12K	1.12M	701.93K	-8.14M	1.69M	-10.86M	140.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.29M	68.99K	3.58M	293.12K	0	-56.2K	3.95M	8.6M	-10.86M	-39K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.04M	-18.06M	-13.74M	-25.8M	34.59M	45.02M	59.35M	116.02M	61.86M	239.25M
FCF Margin %	-	-	-	-51.59%	0.34%	0.38%	0.42%	0.54%	0.16%	0.49%
FCF Growth %	-0.39%	-0%	0.24%	-0.88%	2.34%	0.3%	0.32%	0.95%	-0.47%	2.87%
FCF per Share	-0.22	-0.22	-0.16	-0.25	0.33	0.42	0.55	1.04	0.54	1.91
FCF Conversion (FCF/Net Income)	0.89x	0.99x	0.75x	0.76x	1.09x	0.60x	1.53x	1.40x	2.01x	1.46x
Interest Paid	0	0	0	0	0	0	0	0	705K	1.4M
Taxes Paid	0	0	0	0	0	0	3M	7.67M	50.46M	68.45M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-44.61%	-38.13%	-30.62%	-51.62%	46.06%	58.3%	20.98%	32.76%	20.75%	29.38%
Return on Invested Capital (ROIC)	-57.31%	-54.92%	-57.32%	-91.77%	143.39%	161.1%	99.49%	335.67%	50.14%	62.66%
Gross Margin	-	-	-	-3883.84%	85.57%	85.69%	84.46%	83.94%	86.95%	86%
Net Margin	-	-	-	-6800.7%	31.16%	62.97%	28.03%	38.79%	17.93%	33.33%
Debt / Equity	-	-	-	-	0.01x	0.00x	0.02x	0.01x	0.01x	0.00x
Interest Coverage	-203.19x	-59.95x	-41.13x	-	-	-	-	-	-	-
FCF Conversion	0.89x	0.99x	0.75x	0.76x	1.09x	0.60x	1.53x	1.40x	2.01x	1.46x
Revenue Growth	-	-	-	-	20361.2%	16.39%	18.27%	52.1%	85.9%	23.49%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
Product Revenue Net	-	-	138M	213.94M	396.5M	489.33M
Product Revenue Net Growth	-	-	-	55.03%	85.34%	23.41%
License And Other Revenue	-	-	2.84M	265K	1.7M	2.41M
License And Other Revenue Growth	-	-	-	-90.66%	542.26%	41.42%
Product	102.31M	-	-	-	-	-
Product Growth	-	-	-	-	-	-
Collaborative Arrangement Products Agreement	-	-	-	-	-	-
Collaborative Arrangement Products Agreement Growth	-	-	-	-	-	-

Revenue by Geography

	2019	2020	2021	2022	2023	2024
CANADA	-	33K	-	-	-	-
CANADA Growth	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Catalyst Pharmaceuticals, Inc. (CPRX) has a price-to-earnings (P/E) ratio of 17.7x. This is roughly in line with market averages.

Growth & Financials

Catalyst Pharmaceuticals, Inc. (CPRX) reported $578.2M in revenue for fiscal year 2024.

Catalyst Pharmaceuticals, Inc. (CPRX) grew revenue by 23.5% over the past year. This is strong growth.

Yes, Catalyst Pharmaceuticals, Inc. (CPRX) is profitable, generating $217.6M in net income for fiscal year 2024 (33.3% net margin).

Dividend & Returns

Catalyst Pharmaceuticals, Inc. (CPRX) has a return on equity (ROE) of 29.4%. This is excellent, indicating efficient use of shareholder capital.

Catalyst Pharmaceuticals, Inc. (CPRX) generated $234.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.